ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,965Medicare Part D Prescriptions Filled, Including Refills

Rank: 108 out of 617

$495K Total Retail Price of All Prescriptions

Rank: 105 out of 617

436 Patients Receiving at Least One Drug in Part D
79%Patients 65 Years and Older
45% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nebraska
Lower avg

Schedule Two
Controlled Substances

6% of this provider’s 436 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

12% of this provider’s 436 patients filled at least one prescription for a schedule three drug, compared to an average of 11%.

Risky Drugs to Seniors

0% of this provider’s 7,553 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$50 was the average price of a prescription from this provider, compared to $49 among peers.

Prescriptions per Patient

23 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nebraska
SIMVASTATIN 419 381 1 2
OMEPRAZOLE 383 260 2 3
LEVOTHYROXINE SODIUM 339 275 3 1
LISINOPRIL 307 282 4 5
AMLODIPINE BESYLATE 273 221 5 6
FUROSEMIDE 261 197 6 4
HYDROCODONE-ACETAMINOPHEN 254 135 S3 7 8
POTASSIUM CHLORIDE 241 204 8 10
WARFARIN SODIUM 234 214 9 7
METOPROLOL TARTRATE 218 210 10 11
METOPROLOL SUCCINATE 197 154 11 12
HYDROCHLOROTHIAZIDE 192 170 12 13
PRAVASTATIN SODIUM 185 165 13 21
METFORMIN HCL 171 141 14 9
ZOLPIDEM TARTRATE 160 100 15 23
LISINOPRIL-HYDROCHLOROTHIAZIDE 157 142 16 29
FENOFIBRATE 142 113 17 58
ATENOLOL 137 121 18 17
CRESTOR 136 79 19 28
CARVEDILOL 127 87 20 19
GLIMEPIRIDE 124 93 21 33
ADVAIR DISKUS 103 73 22 38
TRAMADOL HCL 94 80 23 15
ATORVASTATIN CALCIUM 93 84 24 14
CITALOPRAM HBR 91 64 25 18
GABAPENTIN 91 56 25 16
ISOSORBIDE MONONITRATE ER 89 64 27 52
LOSARTAN POTASSIUM 87 72 28 22
NEXIUM 85 33 29 43
VENLAFAXINE HCL ER 83 24 30 76
ALENDRONATE SODIUM 83 73 30 25
ALLOPURINOL 78 72 32 27
PREDNISONE 76 66 33 31
TRAZODONE HCL 75 53 34 51
ZETIA 72 48 35 77
CLOPIDOGREL 69 61 36 53
PROPRANOLOL HCL 65 56 37 109
POLYETHYLENE GLYCOL 3350 64 53 38 32
PAROXETINE HCL 63 53 39 62
OXYBUTYNIN CHLORIDE ER 62 38 40 114
TRICOR 61 29 41 83
ENALAPRIL MALEATE 58 48 42 34
SPIRIVA 57 42 43 61
PANTOPRAZOLE SODIUM 56 55 44 37
MIRTAZAPINE 55 41 45 50
FAMOTIDINE 55 43 45 54
DONEPEZIL HCL 55 53 45 30
CIPROFLOXACIN HCL 53 51 48 60
LANTUS SOLOSTAR 52 36 49 115
PLAVIX 52 47 49 86
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 17, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.